Page 62 - Ip Group News Today

Oxbotica raises $13.8M from Ocado to build autonomous vehicle tech for the online grocer’s logistics network Ocado, the UK online grocer that has been making strides reselling its technology to other grocery companies to help them build and run their own online ordering-and-delivery operations, is making an investment today into what it believes will be the next chapter of how that business will grow: it is taking a £10 million ($13.8 million) stake in Oxbotica, a UK startup that develops au...

By Alec Mattinson2021-04-16T07:55:00+01:00 Top story Ocado has announced a partnership, including a £10m investment, with Oxford based autonomous vehicle software company Oxbotica to develop a range of vehicles. The two will collaborate on hardware and software interfaces for autonomous vehicles, enhancing and integrating Oxbotica’s autonomy software platform into a variety of vehicles. Ocado said the usage will range from vehicles that operate inside of Ocado’s Customer Fulfilment Centr...

Friday, 16 April 2021, 6:05 am Alimetry, a digital healthcare and diagnostic devices start-up, announced today that it has achieved CE Mark for its first product, a pioneering medical device for enabling diagnosis of gastric diseases. The new wearable product, called Gastric Alimetry, is positioned to transform the diagnostic pathway for millions of patients worldwide suffering from diseases such as functional dyspepsia, gastroparesis and chronic nausea and vomiting. Gastric symptoms are extre...

Intrinsic closes £1.35m seed funding round Intrinsic Semiconductor Technologies has announced the close of a £1.35m seed funding round led by investors UCL Technology Fund and IP Group. The funding is intended to help Intrinsic disrupt the $60bn non-volatile memory market by partnering with semiconductor research foundry, imec in Belgium, to develop prototypes of its proprietary nonvolatile memory devices using industry standard ‘complementary metal oxide semi...

The Social Network, the film that depicts the founding of Facebook by Mark Zuckerberg and his Harvard friends, is a compelling drama that also causes viewers idly to speculate: If Id been able to back this university start-up in 2004, how rich would I be now?  Facebook is now an $880bn giant. The share price has risen from $42 in 2012 to $309. Yet its early performance was disappointing, a point to note amid the buzz over Oxford Nanopore, the DNA sequencing technology business spun out from th...

Intrinsic closes £1.35m seed funding round to prototype next generation memory devices March 22, 2021 – London - Memory innovator Intrinsic Semiconductor Technologies Ltd (“Intrinsic”) has announced the close of a £1.35m seed funding round led by investors UCL Technology Fund and IP Group plc. The funding will enable Intrinsic to disrupt the $60bn non-volatile memory market by partnering with leading semiconductor research foundry, imec in Belgium, to develop prototypes of its proprie...

Startup Funding: March 2021 Self-driving vehicles revved up investors in March, with two companies receiving over $200M apiece as they prepare for their systems to enter mass production. One focuses on software for passenger vehicles, while the other is looking to autonomous trucks. Both of the companies received investment from automakers, with China’s largest carmaker SAIC joining each of the funding rounds. It was also a good month for startups making chips for AI acceleration, with four c...

Arix Bioscience PLC: Artios announces collaboration with Novartis to create next generation DDR cancer therapies DJ Artios announces collaboration with Novartis to create next generation DDR cancer therapies Arix Bioscience PLC (ARIX) Artios announces collaboration with Novartis to create next generation DDR cancer therapies 07-Apr-2021 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement....

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies Artios Pharma, Inc.April 7, 2021 GMT Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies. Artios to receive US$20 million up-front payment in addition to near term research funding to support the collaboration. Artios eligib...

Novartis, Artios Pharma Target Cancer in Up-to-$1.3B DDR Collaboration April 7, 2021 Share Artios Pharma CEO Niall Martin, PhD Novartis has agreed to identify and validate next-generation DNA Damage Response (DDR) targets for precision cancer treatments using Artios Pharma’s discovery platform, through a collaboration that could generate more than $1.3 billion for Artios. The companies plan to discover and validate targets that enhance Novartis’ Radioligand Therapies (RLTs) through a three-...